Fund Profile & Information for IBB

iShares Nasdaq Biotechnology Index Fund is an exchange-traded fund incorporated in the USA. The Fund's objective seeks investment results that correspond to the performance of the Nasdaq Biotechnology Index. The Fund will concentrate its investments in companies primarily engaged in using biomedical research for the discovery or development of new treatments or cures for human disease.

Inception Date: 2001-02-09 Telephone: 1-415-597-2000 Managers: GREG SAVAGE Web Site: http://www.ishares.com Fundamentals for IBB NAV (on 2012-02-06) 121.9103 Assets (M) (on 2012-01-31) 1,683.8850 Shares out (M) 14.15 Market Cap (M) 1,724.74 % Premium -0.02 Average 52-Week % Premium -0.0079 Fund Leveraged N Dividends for IBB Dividend Type Income Dividend Frequency Quarter Last Dividend Net - Dividend Yield (ttm) 0.0119 Performance for IBB 1-Month +13.69% 1-Year +29.48% 3-Month +27.00% 3-Year +18.07% Year To Date +16.81% 5-Year +9.08% Expense Ratio 0.48 Top Fund Holdings for IBB Filing Date: 02/03/2012 Amgen Inc 2,016,922 139,732,356 8.256% Alexion Pharmaceuticals Inc 1,415,274 111,629,737 6.596% Gilead Sciences Inc 1,906,869 104,296,200 6.163% Celgene Corp 1,418,932 103,880,012 6.138% Regeneron Pharmaceuticals Inc 975,578 944,944,858 5.583% Biogen Idec Inc 685,802 83,585,548 4.939% Teva Pharmaceutical Industries 1,771,061 80,955,198 4.783% Perrigo Co 668,139 62,577,899 3.698% Vertex Pharmaceuticals Inc 1,460,207 53,706,413 3.173% Mylan Inc/PA 2,187,785 49,093,895 2.901%

More here:
Snapshot for iShares Nasdaq Biotechnology Index Fund (IBB)